Eltrombopag (Side Effects)

In this article, we will discuss Eltrombopag (Adverse/Side Effects). So, let’s get started.

Adverse Reactions

• In adult patients with ITP, the most common adverse reactions (greater
than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.
• In pediatric patients age 1 year and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, and nasopharyngitis.
• In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.
• In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue cough, diarrhea, and headache.

Warnings and Precautions

• Hepatotoxicity: Monitor liver function before and during therapy.
• Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving Eltrombopag (PROMACTA). Monitor platelet counts regularly.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.